Heterogeneity of Alzheimer's disease: consequence for drug trials?
Heterogeneity of Alzheimer's disease: consequence for drug trials?
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Alzheimer's disease is a heterogenous disorder with multiple phenotypes and genotypes, although they eventually converge to a final common clinicopathological endpoint. However, Alzheimer's disease drug trials do not account for the heterogeneity of the disease in trial design, impeding development of effective drugs.
Alzheimer's disease drug tr...
Alternative Titles
Full title
Heterogeneity of Alzheimer's disease: consequence for drug trials?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_cbdccb5cb4da4fd18f20b444c28584c7
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cbdccb5cb4da4fd18f20b444c28584c7
Other Identifiers
ISSN
1758-9193
E-ISSN
1758-9193
DOI
10.1186/s13195-018-0455-y
